Q-omics provides the consensus-scored MTCO2P9 profile across patient tissues and cancer cell-line models. MTCO2P9 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MTCO2P9 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, MTCO2P9 RNA expression shows 5,872 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight BRCA, PRAD, and COAD as cancer lineages where MTCO2P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO2P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO2P9 survival associations across molecular data types. MTCO2P9 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO2P9 RNA expression–survival associations across cancer types. High MTCO2P9 expression shows unfavorable associations in BRCA, ESCA, CESC, UCEC, LGG and STAD. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for MTCO2P9 RNA expression.
This table summarizes MTCO2P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO2P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO2P9 shows higher tumor expression in PRAD. The PRAD box plot shows higher MTCO2P9 RNA expression in tumor versus normal tissue (log2 FC = +0.018, t-test p = .040).
This table shows molecular features associated with MTCO2P9 in patient tissues and cancer cell lines. In patient samples, MTCO2P9 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
